Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00696241 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Azilsartan Medoxomil in Participants With Essential Hypertension
A Phase 3 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,275
- Enrollment target
NCT00696241: Completed Phase 3 study, sponsored by Takeda.
NCT00696241 is a Phase 3 study that has completed, run by Takeda. The registered enrollment target is 1,275 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (65% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00696241, a Phase 3 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,275 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and efficacy of azilsartan medoxomil, once daily (QD), compared to placebo and olmesartan in participants with essential hypertension.
Primary Outcome
The change in 24-hour mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.
Interventions
- DRUG Placebo
- DRUG Olmesartan
- DRUG Azilsartan medoxomil and olmesartan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,275 participants |
| Start Date | 2007-06 |
| Est. Completion | 2008-10 |
| Phase | Phase 3 |
What the finished NCT00696241 record still lists
NCT00696241 is an interventional study that assigns participants to a tested intervention. Its 1,275 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (65% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00696241 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00696241 about?
NCT00696241 is a clinical study titled "Efficacy and Safety of Azilsartan Medoxomil in Participants With Essential Hypertension". The purpose of this study is to determine the safety and efficacy of azilsartan medoxomil, once daily (QD), compared to placebo and olmesartan in participants with essential hypertension.
What is the current status of trial NCT00696241?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,275 participants. The study started on 2007-06. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00696241?
The interventions under investigation include: Placebo (DRUG), Olmesartan (DRUG), Azilsartan medoxomil and olmesartan (DRUG).
Who is sponsoring clinical trial NCT00696241?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00696241's enrollment target sits among peer trials
1,275 200th of 2000 higher than 1,800 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07225504 · 1,275 participants · Phase 3
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
- NCT07001800 · 1,276 participants · Phase 2
Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study
- NCT03678025 · 1,273 participants · Phase 3
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
- NCT03970447 · 1,280 participants · Phase 2
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia